Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

PubWeight™: 0.81^‹?›

🔗 View Article (PMID 27141370)

Published in Oncoimmunology on February 02, 2016

Authors

Zachary A Cooper¹, Alexandre Reuben², Christine N Spencer³, Peter A Prieto², Jacob L Austin-Breneman², Hong Jiang², Cara Haymaker⁴, Vancheswaran Gopalakrishnan², Michael T Tetzlaff⁵, Dennie T Frederick⁶, Ryan J Sullivan⁶, Rodabe N Amaria⁴, Sapna P Patel⁴, Patrick Hwu⁴, Scott E Woodman⁴, Isabella C Glitza⁴, Adi Diab⁴, Luis M Vence⁷, Jaime Rodriguez-Canales⁸, Edwin R Parra⁸, Ignacio I Wistuba⁸, Lisa M Coussens⁹, Arlene H Sharpe¹⁰, Keith T Flaherty⁶, Jeffrey E Gershenwald², Lynda Chin³, Michael A Davies⁴, Karen Clise-Dwyer¹¹, James P Allison⁷, Padmanee Sharma¹², Jennifer A Wargo¹

Author Affiliations

1: Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2: Department of Surgical Oncology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
3: Genomic Medicine, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
4: Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
5: Pathology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
6: Division of Medical Oncology, Massachusetts General Hospital , Boston, MA, USA.
7: Immunology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
8: Translational Molecular Pathology, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
9: Department of Cell, Developmental and Cancer Biology and Knight Cancer Institute, Oregon Health and Science University , Portland, OR, USA.
10: Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School , Boston, MA, USA.
11: Stem Cell Transplantation, University of Texas MD Anderson Cancer Center , Houston, TX, USA.
12: Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Associated clinical trials:

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) | NCT01295827

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175

Articles citing this ↘

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol (2016) 0.86

Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med (2017) 0.75

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Res (2017) 0.75

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology (2017) 0.75

Articles cited by this ↗

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12

Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA Oncol (2015) 1.72

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One (2014) 1.37

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest (2015) 1.22

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. Clin Cancer Res (2015) 1.09

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06

Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer (2014) 0.93

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology (2014) 0.89

Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Semin Oncol (2015) 0.81

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res (2015) 0.79